Breast Cancer,HER2- Cardiac Impact: Trastuzumab Emtansine vs Paclitaxel+Trastuzumab for HER2+ Breast Cancer Mar 27, 2023
Breast Cancer,HER2+ Fam-Trastuzumab Gains FDA Approval for HER2-Low Breast Cancer Treatment Mar 14, 2023
Breast Cancer,HER2+ HER2DX Test Correlates with Trastuzumab/Pertuzumab Therapy in HER2+/HR+ Breast Cancer Mar 14, 2023
Breast Cancer,HER2- Safety Analysis of Palbociclib with Fulvestrant/Letrozole in HR+/HER2- ABC: PARSIFAL Trial Mar 14, 2023
Breast Cancer,TNBC (Triple Negative Breast Cancer) Adjuvant Olaparib Improves OS in High-Risk EBC: OlympiA Phase III Mar 09, 2023
Breast Cancer,TNBC (Triple Negative Breast Cancer) A Phase 3 ASCENT Study on Sacituzumab Govitecan in mTNBC and HRQoL Mar 09, 2023
Breast Cancer,HER2- A Phase 3 Study Analyzing PBO+ET in Advanced HR+ Breast Cancer Subgroups Mar 07, 2023
